Ekta Singh’s Post

We are pleased to announce the "just-happened" implementation of the latest version of the Neuroterminal system, which is type of the innovative MEDIX (Medical Data Information Exchange) system - an advanced compilation of HIS and CIS systems that sets new standards in the field of medicine. A key element of this update is the introduction of the pioneering Neuroscreen® module. This breakthrough functionality acts as a mini-triage, suggesting neurological areas requiring medical attention and indicating the best-matched specialists within the NEUROSPHERA | Centrum Neurologii, Padaczki i Psychiatrii network for a given case. Neuroscreen® is not just a diagnostic tool, but also a clinical decision support system that significantly streamlines the treatment process and improves its effectiveness. This module is an integral part of the MEDIX system, representing the future of medicine through the integration and optimization of medical data flow. We are convinced that practicing neurology without a MEDIX-class system is becoming increasingly challenging in the face of growing case complexity and the volume of medical data. Our system provides comprehensive support in daily practice, allowing doctors to focus on what matters most - patient care. We encourage you to explore the capabilities of the new Neuroterminal version and the Neuroscreen® module. We are confident that these innovations will significantly improve your work and contribute to enhancing the quality of neurological care. #medix #neuroterminal #neurology #cdss #ictal #neuroscreen

Exciting news!🎉 Our team recently published an article in OBM Neurobiology on developing a framework for electronic patient-reported outcomes (ePROs) in neurology. 🧠 The paper proposes a 4-step process for creating customized, mobile-friendly ePRO tools that capture the patient perspective and enhance neurological care and research. 📱 Key steps include: 1- Identifying clinical endpoints and developing repeatable domains/subdomains ✍️ 2- Making the ePRO platform user-friendly and mobile-compatible 📲 3- Building consensus among stakeholders 🤝 4- Validating the ePRO through established methodologies 📈 We believe this framework can revolutionize data collection, empower patients, and enable decentralized clinical trials. 🙌 By incorporating patient-centered digital solutions, we can gain meaningful insights into health outcomes that matter most. 🩺 We are proud of our team for contributing this timely conceptual framework on the future of neurology in the digital age. #ePRO #mHealth #DigitalHealth #Neurology #PatientReportedOutcomes #NeuroCareAI #researchpaper #articlepublication #articleoftheday Junaid Kalia MD TALHA NAZIR Mushhood Ur Rehman Reeda Saeed Osama Zaidat Muhammad Umair

🔬 𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐍𝐞𝐮𝐫𝐨𝐬𝐜𝐢𝐞𝐧𝐜𝐞: 𝐍𝐞𝐮𝐫𝐨𝐞𝐥𝐞𝐜𝐭𝐫𝐨𝐧𝐢𝐜 𝐃𝐞𝐯𝐢𝐜𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 🔬 📄𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐍𝐨𝐰! https://lnkd.in/dEAu3-VP 𝐒𝐮𝐦𝐦𝐚𝐫𝐲: This report describes the global market size of Neuroelectronic Devices from 2019 to 2022 and its CAGR from 2019 to 2023. It also forecasts the market size to the end of 2031, with an expected growth rate of 10.2% CAGR from 2024 to 2031. The Neuroelectronic Devices Market is revolutionizing the field of neuroscience by providing advanced solutions for neurological and sensory disorders, cognitive enhancement, and research. With significant growth projected over the next decade, this market is at the forefront of medical innovation, offering new hope and improved quality of life for patients worldwide. 𝐁𝐲 𝐃𝐞𝐯𝐢𝐜𝐞 𝐓𝐲𝐩𝐞: -Implantable Neuroelectronic Devices -Non-Implantable Neuroelectronic Devices 𝐁𝐲 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧: -Neurological Disorders -Sensory Disorders -Cognitive Enhancement -Research and Diagnostics 𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: -Medtronic -Boston Scientific -Abbott -LivaNova -Cochlear -NeuroPace -Natus Medical Incorporated -Nevro. -Aleva Neurotherapeutics SA -BrainsWay #NeuroelectronicDevices #Medtronic #BostonScientific #Abbott #LivaNova #Cochlear #NeuroPace #NatusMedical #Nevro #AlevaNeurotherapeutics #Brainsway #Neurology #MedicalInnovation #MarketGrowth #SNR Stats And Research

I am happy to share our latest study published in the Academic Journal of Health Sciences (AJHS 2024/39 (1): 74-80): "The effectiveness of three-dimensional(3D) PCASL MR perfusion imaging in assessing cognitive status in patients with mild cognitive impairment and Alzheimer’s disease". We aimed to evaluate the relationship between CBF values obtained through non-contrast PCASL MRI imaging and scores from Mini Mental State Examination(MMSE), Clinical Dementia Rating(CDR), and Cognitive Disability Score(CDS) tests in patients diagnosed with mild cognitive impairment and Alzheimer’s disease. PCASL MR imaging detects neurodegenerative changes in Alzheimer’s and its milder forms, supplementing neuropsychiatric evaluations like the mini-mental test. When contrasted with FDG-PET imaging, ASL MR perfusion stands out due to its non-invasive nature, absence of radiation exposure, and cost-effectiveness. Its easy applicability further underscores its prominence as a preferred diagnostic tool in assessing dementia. #alzheimer #dementia #mri #perfusion #neurology #radiology

We are very proud that Biomedicines MDPI has published an article on our landmark phase 1b study with STP1. STP1 is a novel combination therapy tailored for the treatment of a clinically and biologically defined subgroup of patients with autism spectrum disorder (ASD), named ASD Phenotype 1 (ASD-Phen1). The study is a significant milestone, as a first-of-its-kind stratification-based approach for clinical development in neurodevelopmental disorders. This demonstrates the potential of precision medicine in ASD. “The electrophysiological signals from this study are remarkable and represent the strongest early trial target engagement signals our lab has seen in the autism field,” said Dr. Craig Erickson, the principal investigator of the study. Click here for the full article in Biomedicines https://lnkd.in/gN74-fNS STALICLA press release: https://lnkd.in/g7AwGkFV #biotech #neurology #ASD #precisionmedicine #innovation 

I was delighted to know that one of our research papers (which was published in July, 2022) entitled: "AstraZeneca COVID-19 vaccine: A possible risk factor for ischemic stroke and cerebral venous sagittal sinus thrombosis: A case series" stands out as one of the most widely read and downloaded papers in "Wiley Clinical Case Reports" and I was honoured to receive a certificate regarding this matter. Link: https://lnkd.in/d44GCwtx #medicine #research #researchpapers #researchers #publications #covid19 #covid19vaccine #covid19pandemic #covid19research #covid #physicians #stroke #thrombosis #neurology #neurologists

Hope for ALS: Brain implants enable speech recovery🔬 Groundbreaking research in the field of medical science opens a ray of hope for patients suffering from ALS - Amyotrophic Lateral Sclerosis. ALS is an excruciating condition that weakens muscles and affects nerve cells in the brain and spinal cord, often leading to loss of speech and movement. 🚑💔 🎉 But here is some remarkable news! Pioneering brain implants are now capable of decoding the signals linked to speech, thereby enabling ALS patients to communicate. Furthermore, this breakthrough has the potential to pave the way for solutions for other neurological disorders. 🧠✨ Hope prevails in the face of adversity. The future of neurology promises tremendous progress in medical science and is unimaginably beneficial for ALS patients. As modern science rightly points out, 'You may have lost your speech, but not your voice.' 💪🎯 Let's continue to believe in the power of medical research and strive relentlessly for a better tomorrow. For an in-depth read on this fascinating development, click on the link below: [Read More 👉](https://lnkd.in/dC2PCHBK) #ALS #Neurology #MedicalResearch #BrainImplants #Hope #Progress

Atrial fibrillation (AF) and intracranial hemorrhage (ICH) present a complex clinical challenge due to the dual risks of ischemic and hemorrhagic events. #AF patients on oral #anticoagulants (OACs) are at increased risk for #ICH, which accounts for 10%-15% of all #strokes. Managing OACs in ICH survivors is controversial as it can reduce ischemic stroke risk but may increase ICH recurrence. Recent studies suggest non-vitamin K oral anticoagulants (NOACs) like apixaban may offer a safer profile compared to warfarin, showing lower ICH rates and mortality. Optimal anticoagulation strategies require individualized, interdisciplinary approaches. It is good to hear that progressive treatment of ICH can provide good outcome for AF patients. References: Hill, J., et al. (2024) 'Predictive model for ICH risk in AF patients on anticoagulants', *Journal of Stroke and Cerebrovascular Diseases*, 33(2): 123-130, doi:10.1016/j.jstrokecerebrovasdis.2023.106900. Simonsen, C.Z., et al. (2023) 'Intracranial hemorrhage in patients with atrial fibrillation on oral anticoagulants', *Stroke*, 54(1): 45-52, doi:10.1161/STROKEAHA.122.038400.

Intriguing news in the field of Alzheimer's research: a small study just published in the NEJM shows that focused ultrasound-based (FUS) blood-brain barrier (BBB) opening can greatly enhance the effectiveness of aducanumab in lowering amyloid levels in targeted brain regions. In the study, three patients were treated with aducanumab for 6 months while simultaneously undergoing FUS. The results were quite spectacular, compared to intravenously administered aducanumab alone or other anti-amyloid antibodies. While there are still many things to sort out before this could potentially be used in clinical practice, FUS is an interesting technology to get sufficient drug exposure in the brain. Check out the study here: https://lnkd.in/eZ3kS-kS. Thanks to Peng Leong for bringing this to our attention. #Alzheimers #technology #science #neuroscience #healthcare

【World Brain Day – managing risk factors of intracerebral hemorrhage】 The Division of Neurology at CU Medicine conducted the world’s first population-based study comparing the use of prothrombin complex concentrate (a coagulation factor concentrate) versus conservative treatment for Chinese patients with atrial fibrillation (AF) who have developed intracerebral hemorrhage. The results showed that among those patients, prothrombin complex concentrate treatment did not significantly improve recovery outcomes compared to conservative treatment, and there is an urgent need to explore effective treatment for intracerebral hemorrhage patients. In collaboration with CUHK’s Department of Imaging and Interventional Radiology and Department of Computer Science and Engineering, the Neurology team has developed an AI imaging analysis algorithm that can spot blood clots formed in intracerebral hemorrhage and analyse the volume and expansion of the blood clots through clinical and imaging data. Today (July 22) is the World Brain Day, as intracerebral hemorrhage associated with high morbidity and mortality, the research team calls on the public to maintain a healthy lifestyle. For AF patients, they should strictly manage risk factors that can lead to intracerebral hemorrhage, manage their blood pressure and avoid falls or injuries. The research findings have been published in top international medical journal JAMA Network Open. Details: https://bit.ly/3y7oUb0 Full article: https://bit.ly/3Wz68Tz #CUMedicine #WorldBrainDay #Neurology #AtrialFibrillation